biostudies-literatureUnknown12Raphael A<h4>Background</h4>The use of CGP in guiding treatment decisions in aNSCLC with acquired resistance to ALK TKIs is questionable.<h4>Methods</h4>We prospectively assessed the impact of CGP on the decision-making process in ALK-rearranged aNSCLC patients following progression on 2^nd/3^rd-generation ALK TKIs. Physician's choice of the most recommended next-line systemic treatment (NLST) was captured before and after receival of CGP results; the percentage of cases in which the NLST recommendation has changed was assessed along with the CGP turnaround time (TAT). Patients were divided into groups: patients in whom the NLST was initiated after (group 1) and before (group 2) receival of the CGP results. Time-to-treatment discontinuation (TTD) and overall survival (OS) with NFrontiers in oncology874712https://www.ebi.ac.uk/biostudies/studies/S-EPMC9137396biostudies-literatureThe Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2^nd/3^rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs).PMC9137396Peled NDudnik JZer ACohen AYDudnik EMoskovitz MKian WBar JShochat TAgbarya ARaphael AOedegaard CGrynberg SHoltzman LUrban DOnn ARabinovich NMfalseThe Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2^nd/3^rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs).<h4>Background</h4>The use of CGP in guiding treatment decisions in aNSCLC with acquired resistance to ALK TKIs is questionable.<h4>Methods</h4>We prospectively assessed the impact of CGP on the decision-making process in ALK-rearranged aNSCLC patients following progression on 2^nd/3^rd-generation ALK TKIs. Physician's choice of the most recommended next-line systemic treatment (NLST) was captured before and after receival of CGP results; the percentage of cases in which the NLST recommendation has changed was assessed along with the CGP turnaround time (TAT). Patients were divided into groups: patients in whom the NLST was initiated after (group 1) and before (group 2) receival of the CGP results. Time-to-treatment discontinuation (TTD) and overall survival (OS) with N2022-01-01T00:00:00Z20222025-05-29T14:36:28.506Z2025-02-19T02:16:19.474ZS-EPMC91373963564670710.3389/fonc.2022.874712